Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.
Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.
Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.
The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.